Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01902459 · ClinicalTrials.gov registry record · Phase 4
EVARREST™ Fibrin Sealant Patch Post-Market Study
A Phase 4 study, sponsored by Ethicon.
- Completed
- Registry status
- Phase 4
- Development phase
- 150
- Enrollment target
NCT01902459 is a Phase 4 study that has completed, run by Ethicon. The registered enrollment target is 150 participants.
The verdict
NCT01902459, a Phase 4 study, has completed, sponsored by Ethicon.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 150 participants
- Enrollment target
Study Summary
The objective of this study is to evaluate the clinical utility of EVARREST™ Fibrin Sealant Patch (Fibrin Pad) as an adjunct to hemostasis in soft tissue bleeding during intra-abdominal (stomach area), retroperitoneal (hip and stomach area), pelvic (hip area) and non-cardiac thoracic (chest area) surgery.
Interventions
- OTHER Standard of Care
- BIOLOGICAL EVARREST™ Fibrin Sealant Patch
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2013-07-01 |
| Est. Completion | 2015-09-01 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01902459
The ClinicalTrials.gov registry entry for NCT01902459 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 150 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ethicon, which has 38 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Standard of Care is the first listed.
NCT01902459 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01902459 about?
NCT01902459 is a clinical study titled "EVARREST™ Fibrin Sealant Patch Post-Market Study". The objective of this study is to evaluate the clinical utility of EVARREST™ Fibrin Sealant Patch (Fibrin Pad) as an adjunct to hemostasis in soft tissue bleeding during intra-abdominal (stomach area), retroperitoneal (hip and stomach area), pelvic (hip area) and non-cardiac thoracic (chest area) su...
What is the current status of trial NCT01902459?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 150 participants. The study started on 2013-07-01. Estimated completion is 2015-09-01.
What interventions are being tested in trial NCT01902459?
The interventions under investigation include: Standard of Care (OTHER), EVARREST™ Fibrin Sealant Patch (BIOLOGICAL).
Who is sponsoring clinical trial NCT01902459?
This trial is sponsored by Ethicon, which has 38 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.